AbbVie Inc. Shares (NYSE:ABBV) sold by Sompo Asset Management Co. Ltd.

Sompo Asset Management Co. Ltd. reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 5,630 shares of the company’s stock after selling 170 shares during the period. The holdings of Sompo Asset Management Co. Ltd.’s holdings in AbbVie were worth $966,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Frisch Financial Group Inc. increased its position in AbbVie by 0.8% during the second quarter. Frisch Financial Group Inc. now owns 6,920 shares of the company’s stock worth $1,187,000 after acquiring an additional 53 shares during the period. Capital Advisors Ltd. LLC grew its position in AbbVie by 1.3% during the second quarter. Capital Advisors Ltd. LLC now owns 4,453 shares of the company’s stock worth $764,000 after acquiring an additional 55 shares during the period. Hilltop Partners LLC grew its position in AbbVie by 1.4% during the second quarter. Hilltop Partners LLC now owns 3,859 shares of the company’s stock worth $662,000 after acquiring an additional 55 shares during the period. Lokken Investment Group LLC grew its position in AbbVie by 3.6% during the fourth quarter. Lokken Investment Group LLC now owns 1,666 shares of the company’s stock worth $258,000 after acquiring an additional 58 shares during the period. Finally, Longfellow Investment Management Co. LLC grew its position in AbbVie by 1.0% during the second quarter. Longfellow Investment Management Co. LLC now owns 5,622 shares of the company’s stock worth $964,000 after acquiring an additional 58 shares during the period. 70.23% of the shares are currently owned by institutional investors and hedge funds.

Analysts on Wall Street are forecasting an increase

A number of equities research analysts have recently commented on the stock. BMO Capital Markets upped their target price on shares of AbbVie from $180.00 to $214.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. William Blair upgraded shares of AbbVie to a “strong-buy” rating in a research report on Friday, August 30th. Truist Financial reiterated a “buy” rating and issued a $210.00 target price (up from $195.00) on shares of AbbVie in a research report on Friday, July 26th. Barclays boosted their target price on shares of AbbVie from $187.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 26th. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $190.00 target price on shares of AbbVie in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. AbbVie has an average rating of “Buy” and an average price target of $191.64, according to MarketBeat .

Read the latest research report on AbbVie

AbbVie stock fell 0.1%

Shares of ABBV stock opened at $193.46 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.71, and a debt-to-equity ratio of 8.51. AbbVie Inc. has a 12-month low of $135.85 and a 12-month high of $199.95. The company’s 50-day moving average is $189.35, and its two-hundred-day moving average is $175.82. The stock has a market cap of $341.62 billion, a P/E ratio of 57.41, a PEG ratio of 2.66 and a beta of 0.64.

AbbVie (NYSE:ABBV – Get Your Free Report ) last issued its quarterly earnings data on Thursday, July 25th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.08. AbbVie had a net margin of 9.71% and a return on equity of 203.66%. The company had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.02 billion. In the same quarter last year, the company earned $2.91 per share. The company’s revenue for the quarter was up 4.3% year-over-year. Research analysts expect that AbbVie Inc. to post 10.86 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $1.55 dividend. The ex-dividend date is Tuesday, October 15th. This represents a dividend of $6.20 on an annualized basis and a dividend yield of 3.20%. AbbVie’s payout ratio is 183.98%.

Insider activity at AbbVie

In related news, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.00. Following the transaction, the chairman now directly owns 446,599 shares in the company, valued at approximately $83,299,645.48. The transaction was disclosed in a legal filing with the SEC, which is accessible via this link. In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the sale, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total value of $12,403,580.00. Following the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. The disclosure for this sale can be found here. 0.25% of shares are currently owned by insiders.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures and sells pharmaceutical products worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet’s disease and pyoderma gangrenosum; Skyrizi for the treatment of moderate to severe plaque psoriasis, psoriatic disease and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s disease; Imbruvica for the treatment of adult patients with blood cancer; Epkinly for treating lymphoma; Elahere for the treatment of cancer; and Venclexta/Venclyxto to treat blood cancers.

Read more

Want to see what other hedge funds ABBV owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for AbbVie Inc. (NYSE:ABBV – Free Report).

Get news and reviews for AbbVie Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AbbVie and related companies with MarketBeat.com’s FREE daily email newsletter.